These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

493 related articles for article (PubMed ID: 31433986)

  • 1. Complement C3 Is Activated in Human AD Brain and Is Required for Neurodegeneration in Mouse Models of Amyloidosis and Tauopathy.
    Wu T; Dejanovic B; Gandham VD; Gogineni A; Edmonds R; Schauer S; Srinivasan K; Huntley MA; Wang Y; Wang TM; Hedehus M; Barck KH; Stark M; Ngu H; Foreman O; Meilandt WJ; Elstrott J; Chang MC; Hansen DV; Carano RAD; Sheng M; Hanson JE
    Cell Rep; 2019 Aug; 28(8):2111-2123.e6. PubMed ID: 31433986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complement C3 and C4 expression in C1q sufficient and deficient mouse models of Alzheimer's disease.
    Zhou J; Fonseca MI; Pisalyaput K; Tenner AJ
    J Neurochem; 2008 Sep; 106(5):2080-92. PubMed ID: 18624920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Astrocyte-Microglia Cross Talk through Complement Activation Modulates Amyloid Pathology in Mouse Models of Alzheimer's Disease.
    Lian H; Litvinchuk A; Chiang AC; Aithmitti N; Jankowsky JL; Zheng H
    J Neurosci; 2016 Jan; 36(2):577-89. PubMed ID: 26758846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice.
    Shi Q; Chowdhury S; Ma R; Le KX; Hong S; Caldarone BJ; Stevens B; Lemere CA
    Sci Transl Med; 2017 May; 9(392):. PubMed ID: 28566429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice.
    Wyss-Coray T; Yan F; Lin AH; Lambris JD; Alexander JJ; Quigg RJ; Masliah E
    Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10837-42. PubMed ID: 12119423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of complement system components during aging and amyloid deposition in APP transgenic mice.
    Reichwald J; Danner S; Wiederhold KH; Staufenbiel M
    J Neuroinflammation; 2009 Nov; 6():35. PubMed ID: 19917141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contribution of complement activation pathways to neuropathology differs among mouse models of Alzheimer's disease.
    Fonseca MI; Chu SH; Berci AM; Benoit ME; Peters DG; Kimura Y; Tenner AJ
    J Neuroinflammation; 2011 Jan; 8(1):4. PubMed ID: 21235806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in the Synaptic Proteome in Tauopathy and Rescue of Tau-Induced Synapse Loss by C1q Antibodies.
    Dejanovic B; Huntley MA; De Mazière A; Meilandt WJ; Wu T; Srinivasan K; Jiang Z; Gandham V; Friedman BA; Ngu H; Foreman O; Carano RAD; Chih B; Klumperman J; Bakalarski C; Hanson JE; Sheng M
    Neuron; 2018 Dec; 100(6):1322-1336.e7. PubMed ID: 30392797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complement C3aR Inactivation Attenuates Tau Pathology and Reverses an Immune Network Deregulated in Tauopathy Models and Alzheimer's Disease.
    Litvinchuk A; Wan YW; Swartzlander DB; Chen F; Cole A; Propson NE; Wang Q; Zhang B; Liu Z; Zheng H
    Neuron; 2018 Dec; 100(6):1337-1353.e5. PubMed ID: 30415998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibiting the formation of classical C3-convertase on the Alzheimer's beta-amyloid peptide.
    Emmerling MR; Spiegel K; Watson MD
    Immunopharmacology; 1997 Dec; 38(1-2):101-9. PubMed ID: 9476121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cannabinoid CB2 Receptors in a Mouse Model of Aβ Amyloidosis: Immunohistochemical Analysis and Suitability as a PET Biomarker of Neuroinflammation.
    Savonenko AV; Melnikova T; Wang Y; Ravert H; Gao Y; Koppel J; Lee D; Pletnikova O; Cho E; Sayyida N; Hiatt A; Troncoso J; Davies P; Dannals RF; Pomper MG; Horti AG
    PLoS One; 2015; 10(6):e0129618. PubMed ID: 26086915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of complement proteins in a mouse model for cerebral microvascular A beta deposition.
    Fan R; DeFilippis K; Van Nostrand WE
    J Neuroinflammation; 2007 Sep; 4():22. PubMed ID: 17877807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complement and microglia mediate early synapse loss in Alzheimer mouse models.
    Hong S; Beja-Glasser VF; Nfonoyim BM; Frouin A; Li S; Ramakrishnan S; Merry KM; Shi Q; Rosenthal A; Barres BA; Lemere CA; Selkoe DJ; Stevens B
    Science; 2016 May; 352(6286):712-716. PubMed ID: 27033548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The neuronal pentraxin Nptx2 regulates complement activity and restrains microglia-mediated synapse loss in neurodegeneration.
    Zhou J; Wade SD; Graykowski D; Xiao MF; Zhao B; Giannini LAA; Hanson JE; van Swieten JC; Sheng M; Worley PF; Dejanovic B
    Sci Transl Med; 2023 Mar; 15(689):eadf0141. PubMed ID: 36989373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complement C1q-C3-associated synaptic changes in multiple sclerosis hippocampus.
    Michailidou I; Willems JG; Kooi EJ; van Eden C; Gold SM; Geurts JJ; Baas F; Huitinga I; Ramaglia V
    Ann Neurol; 2015 Jun; 77(6):1007-26. PubMed ID: 25727254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Terminal complement pathway activation drives synaptic loss in Alzheimer's disease models.
    Carpanini SM; Torvell M; Bevan RJ; Byrne RAJ; Daskoulidou N; Saito T; Saido TC; Taylor PR; Hughes TR; Zelek WM; Morgan BP
    Acta Neuropathol Commun; 2022 Jul; 10(1):99. PubMed ID: 35794654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A NH2 tau fragment targets neuronal mitochondria at AD synapses: possible implications for neurodegeneration.
    Amadoro G; Corsetti V; Stringaro A; Colone M; D'Aguanno S; Meli G; Ciotti M; Sancesario G; Cattaneo A; Bussani R; Mercanti D; Calissano P
    J Alzheimers Dis; 2010; 21(2):445-70. PubMed ID: 20571215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrative approach to sporadic Alzheimer's disease: deficiency of TYROBP in a tauopathy mouse model reduces C1q and normalizes clinical phenotype while increasing spread and state of phosphorylation of tau.
    Audrain M; Haure-Mirande JV; Wang M; Kim SH; Fanutza T; Chakrabarty P; Fraser P; St George-Hyslop PH; Golde TE; Blitzer RD; Schadt EE; Zhang B; Ehrlich ME; Gandy S
    Mol Psychiatry; 2019 Sep; 24(9):1383-1397. PubMed ID: 30283031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model.
    Shi Y; Manis M; Long J; Wang K; Sullivan PM; Remolina Serrano J; Hoyle R; Holtzman DM
    J Exp Med; 2019 Nov; 216(11):2546-2561. PubMed ID: 31601677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tauopathy contributes to synaptic and cognitive deficits in a murine model for Alzheimer's disease.
    Stancu IC; Ris L; Vasconcelos B; Marinangeli C; Goeminne L; Laporte V; Haylani LE; Couturier J; Schakman O; Gailly P; Pierrot N; Kienlen-Campard P; Octave JN; Dewachter I
    FASEB J; 2014 Jun; 28(6):2620-31. PubMed ID: 24604080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.